+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Erectile Dysfunction Drugs Market by Sales Model, Treatment Duration, Distribution Channel, Dosage Strength, Patient Age Group - Global Forecast to 2030- Product Image
Erectile Dysfunction Drugs Market by Sales Model, Treatment Duration, Distribution Channel, Dosage Strength, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Erectile Dysfunction Drugs Market by Sales Model, Treatment Duration, Distribution Channel, Dosage Strength, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4989691
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The erectile dysfunction drugs market is rapidly evolving, shaped by technological advancements, regulatory changes, and shifting patient needs. Senior decision-makers face a dynamic competitive landscape that demands agile strategies to capture opportunity and manage risks effectively.

Market Snapshot: Erectile Dysfunction Drugs Market Overview

According to recent research, the erectile dysfunction drugs market grew from USD 2.59 billion in 2024 to USD 2.79 billion in 2025 and is projected to reach USD 3.99 billion by 2030. The market is expanding at a compound annual growth rate of 7.44%. This upward trend is supported by both expanded patient access and a broader array of treatment options. Patent expirations for established therapies and the emergence of next-generation formulations continue to drive market transformation.

Scope & Segmentation

The report provides an in-depth analysis of the erectile dysfunction drugs market, evaluating it across critical segments, geographies, and innovations:

  • Sales Model: Branded and generic products influence both pricing strategies and market expansion, addressing diverse prescriber and patient needs.
  • Treatment Duration: Long-term management options support chronic care, while short-term therapies address intermittent requirements.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies each contribute unique market reach, responding to both institutional and community-based demand.
  • Dosage Strength: Products are tailored across 25 mg, 50 mg, and 100 mg strengths to accommodate different patient profiles and dosing preferences.
  • Patient Age Groups: Segmentation spans individuals under 40, those aged 40–60, and populations over 60, reflecting varied therapeutic goals and risk factors.
  • Regions Covered: Americas (including the US, Canada, Brazil, Mexico, Argentina, and select US states); Europe, Middle East & Africa (with major markets such as Germany, France, the United Kingdom, Russia, Saudi Arabia, and South Africa); and Asia-Pacific (featuring China, India, Japan, Australia, South Korea, and others).
  • Key Technologies: Increased adoption of telemedicine platforms, digital health integrations, and real-world evidence methodologies are driving both product innovation and patient engagement.
  • Company Coverage: Major industry leaders such as Pfizer Inc., Eli Lilly and Company, Bayer AG, Teva Pharmaceutical Industries Ltd., and several others are profiled, detailing their strategies and product offerings.

Key Takeaways for Decision-Makers

  • Major pharmaceutical firms are focusing on incremental innovation and digital integration to enhance patient access and differentiate their offerings.
  • Rising demand for generic alternatives is intensifying price competition, which is widening patient access but compressing margins.
  • Telehealth adoption is streamlining consultation and prescription processes, requiring adjustment of engagement and fulfillment strategies.
  • Expanded public health initiatives are supporting earlier intervention, growing the addressable market, and elevating brand development opportunities.
  • New delivery formats, such as topical and sublingual formulations, cater to unmet patient preferences for convenience and rapid onset.
  • Collaborative partnerships—both in supply chain diversification and digital health integration—are emerging as strategic levers for market resilience and sustainable growth.

Tariff Impact

Recent US tariffs on imported active pharmaceutical ingredients have increased production costs for both branded and generic erectile dysfunction drugs. Manufacturers are adjusting sourcing strategies by exploring domestic production and re-negotiating supplier terms. These changes have influenced pricing models, supply chain dynamics, and reimbursement negotiations with payers. Patient assistance and affordability initiatives are also expanding to maintain treatment accessibility, underscoring the need for strategic adaptation to regulatory shifts.

Methodology & Data Sources

This report utilizes a blended approach of primary and secondary research. Industry experts, healthcare providers, and senior executives were interviewed for qualitative insights. Secondary sources include regulatory filings, clinical trial data, industry publications, and trade databases. All data undergoes robust validation through triangulation and peer review to ensure integrity.

Why This Report Matters

  • Enables executives to anticipate market shifts and proactively navigate regulatory and competitive headwinds.
  • Offers segmentation and regional intelligence to refine go-to-market strategies and optimize investments for both current and emerging markets.
  • Delivers actionable recommendations on product development, digital health integration, and supply chain resilience for sustained business performance.

Conclusion

This comprehensive report equips industry leaders to make data-driven, agile decisions amid evolving market dynamics. Leveraging these insights supports improved patient outcomes, operational efficiency, and long-term competitive positioning.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Erectile Dysfunction Drugs Market, by Sales Model
8.1. Introduction
8.2. Branded
8.3. Generic
9. Erectile Dysfunction Drugs Market, by Treatment Duration
9.1. Introduction
9.2. Long-Term
9.3. Short-Term
10. Erectile Dysfunction Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Erectile Dysfunction Drugs Market, by Dosage Strength
11.1. Introduction
11.2. 100 Mg
11.3. 25 Mg
11.4. 50 Mg
12. Erectile Dysfunction Drugs Market, by Patient Age Group
12.1. Introduction
12.2. 40-60 Years
12.3. 60+ Years
12.4. Under 40 Years
13. Americas Erectile Dysfunction Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Erectile Dysfunction Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Erectile Dysfunction Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Eli Lilly and Company
16.3.3. Bayer AG
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. Viatris Inc.
16.3.6. Sandoz International GmbH
16.3.7. Dr. Reddy's Laboratories Ltd.
16.3.8. Sun Pharmaceutical Industries Ltd.
16.3.9. Aurobindo Pharma Limited
16.3.10. Cipla Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ERECTILE DYSFUNCTION DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ERECTILE DYSFUNCTION DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ERECTILE DYSFUNCTION DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 100 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 25 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 50 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 40-60 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY 60+ YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY UNDER 40 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 37. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 40. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 68. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 69. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 71. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 72. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 73. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 74. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 76. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 78. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 83. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 84. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 86. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 88. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 89. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 91. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 97. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 98. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 99. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 103. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 104. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 108. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 111. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 118. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 119. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 121. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 123. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 124. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 126. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 143. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 144. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 146. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 148. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 149. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 153. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 154. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 156. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 158. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 159. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 161. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 163. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 164. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 174. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 175. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 177. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 179. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 180. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 182. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 184. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 185. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 187. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 204. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 205. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 207. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SALES MODEL, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 234. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Erectile Dysfunction Drugs market report include:
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Cipla Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.99 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Erectile Dysfunction Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Erectile Dysfunction Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 81 Pages
  • Global
From
Erectile Dysfunction (ED) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033 - Product Image

Erectile Dysfunction (ED) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • Report
  • 180 Pages
  • Global
From
Drugs for Erectile Dysfunction Market Report 2025 - Product Image

Drugs for Erectile Dysfunction Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Erectile Dysfunction Drugs - Global Strategic Business Report - Product Image

Erectile Dysfunction Drugs - Global Strategic Business Report

  • Report
  • 287 Pages
  • Global
From

About the Erectile Dysfunction Drug Market

The Erectile Dysfunction Drug market is a subset of the Sexual and Reproductive Health Drugs market. These drugs are used to treat erectile dysfunction, a condition in which a man is unable to achieve or maintain an erection sufficient for sexual intercourse. Common treatments include phosphodiesterase type 5 inhibitors, such as sildenafil, tadalafil, and vardenafil, as well as testosterone replacement therapy. These drugs are typically prescribed by a doctor and can be taken orally or injected directly into the penis. The Erectile Dysfunction Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Pfizer, Eli Lilly, Bayer, Merck, and GlaxoSmithKline. Other companies include Teva Pharmaceuticals, Sun Pharmaceuticals, and Cipla. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.